Global Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023
A key factor driving the growth of the market is the high prevalence of
AMD. Our market experts have identified that globally, the prevalence of
AMD is very high, owing to the presence of high-risk factors for
developing the condition. Risk factors such as aging, smoking, high
cholesterol, and high blood pressure are the major contributors to the
development of AMD. Moreover, despite the high prevalence of AMD, no
approved therapies are available in the market for the treatment of the
condition. Thus, the high prevalence coupled with the huge unmet medical
need of dry AMD is expected to drive the market growth during the
forecast period.
Global age-related macular degeneration (AMD) therapeutics market: Development of gene therapy for AMD
At present, only a few drugs are approved for the treatment of AMD. However, the side effects associated with them are very severe, and the majority of them act against VEGF only. Hence, there is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.
Global age-related macular degeneration (AMD) therapeutics market: Segmentation analysis
This market research report segments the global age-related macular degeneration (AMD) therapeutics market by type (wet AMD and dry AMD) and geographical regions (North America, Europe, Asia, ROW).
Global age-related macular degeneration (AMD) therapeutics market: Development of gene therapy for AMD
At present, only a few drugs are approved for the treatment of AMD. However, the side effects associated with them are very severe, and the majority of them act against VEGF only. Hence, there is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.
Global age-related macular degeneration (AMD) therapeutics market: Segmentation analysis
This market research report segments the global age-related macular degeneration (AMD) therapeutics market by type (wet AMD and dry AMD) and geographical regions (North America, Europe, Asia, ROW).
Comments
Post a Comment